Comparative Analysis of the Capsid Structures of AAVrh.10, AAVrh.39, and AAV8

Mario Mietzsch, Candace Barnes, Joshua A. Hull, Paul R. Chipman, Jun Xie, Nilakshee Bhattacharya, Duncan Sousa, Robert McKenna, Guangping Gao, Mavis Agbandje‐McKenna

Journal of Virology · 2019 · 68 citations · 81 references

DOIFull text

Open access

Concepts

Abstract

Recombinant adeno-associated virus vectors (rAAVs), based on AAV8 and AAVrh.10, have been utilized in multiple clinical trials to treat different monogenetic diseases. The closely related AAVrh.39 has also shown promise in vivo . As recently attained for other AAV biologics, e.g., Luxturna and Zolgensma, based on AAV2 and AAV9, respectively, the vectors in this study will likely gain U.S. Food and Drug Administration approval for commercialization in the near future. This study characterized the capsid structures of these clinical vectors at atomic resolution using cryo-electron microscopy and image reconstruction for comparative analysis. The analysis suggested two key residues, S269 and N472, as determinants of BBB crossing for AAVrh.10 and AAVrh.39, a feature utilized for central nervous system delivery of therapeutic genes. The structure information thus provides a platform for engineering to improve receptor retargeting or tissue specificity. These are important challenges in the field that need attention. Capsid structure information also provides knowledge potentially applicable for regulatory product approval.

References

81